Physician profile
Melaku Demede
NPI 1396935763
$8,325.26
in general payments reported to CMS, 2019-2025
29 companies · $4,033 in 2025
The $4,033 reported for 2025 was more than what 80% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $964 · 2020: $324 · 2021: $625 · 2022: $563 · 2023: $813 · 2024: $1,003 · 2025: $4,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,275 · Travel and Lodging: $2,565 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,275.11 |
| Travel and Lodging | $2,565.48 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,545.91 | 2020-2025 | Xience Skypoint, Pressurewire, Coroflow |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,126.67 | 2019-2025 | Lifevest |
| Medtronic, INC. | $956.20 | 2021-2025 | Venaseal |
| Shockwave Medical, INC | $519.27 | 2024-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave E8 Peripher |
| Astrazeneca Pharmaceuticals LP | $497.99 | 2019-2024 | Farxiga, Brilinta, Wainua |
| Kestra Medical Technology Services, INC. | $418.09 | 2022-2025 | Assure Wcd |
| Terumo Medical Corporation | $388.94 | 2019-2023 | Glidesheath Slender |
| Boston Scientific Corporation | $376.58 | 2019-2025 | General - Therapies, Synergy, General - Balloon Catheters |
| Novartis Pharmaceuticals Corporation | $360.29 | 2019-2024 | |
| Philips North America LLC | $192.82 | 2023-2025 | Ineb Devices, (Bq9) Coronary Ivus, (P88) Igt Devices Fm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.19 | 2021-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $158.09 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $118.94 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $113.58 | 2020-2022 | |
| Pfizer INC. | $110.32 | 2019-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $43.81 | 2021-2024 | Onpattro |
| Medtronic Vascular, INC. | $23.83 | 2020 | |
| Abiomed | $22.53 | 2025 | |
| Acist Medical Systems, INC. | $22.32 | 2024 | |
| Lexicon Pharmaceuticals, INC. | $21.54 | 2024 | |
| Novo Nordisk INC | $20.50 | 2025 | Wegovy |
| Osprey Medical INC | $19.64 | 2021 | |
| Cardiovascular Systems INC. | $19.11 | 2021 | |
| Biotronik INC. | $16.67 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $15.69 | 2024 | Arcalyst |
| Akcea Therapeutics, INC. | $15.06 | 2020 | |
| Baxter Healthcare | $13.90 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Lantheus Medical Imaging, INC. | $12.77 | 2019 | |
| Cvrx, INC. | $10.01 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melaku Demede listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.